O'Neill Gilmore Neil, CEO of Editas Medicine ($EDIT), made four open market sales of company shares over the past year, totaling $63,671. His most recent sale occurred on March 3, 2026. These transactions rank 10,113th out of 11,678 insiders in our database, well below the average sale value of $8.6 million across 6.4 transactions per insider. He reported no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 12, 2026 | Editas Medicine, Inc. | $EDIT | O'Neill Gilmore Neil | CEO | A | Stock Option (right to buy) | 1015200 | $0.00 | 1,015,200.0000 | 97,618,660 | 9999.99% | 1.04% |
| March 3, 2026 | Editas Medicine, Inc. | $EDIT | O'Neill Gilmore Neil | CEO | S | Common Stock | 5394 | $2.02 | 263,693.0000 | 97,618,660 | 2.00% | 0.01% |
| Dec. 3, 2025 | Editas Medicine, Inc. | $EDIT | O'Neill Gilmore Neil | CEO | S | Common Stock | 5603 | $2.15 | 269,087.0000 | 97,618,660 | 2.04% | 0.01% |
| Sept. 3, 2025 | Editas Medicine, Inc. | $EDIT | O'Neill Gilmore Neil | CEO | S | Common Stock | 5592 | $2.60 | 274,690.0000 | 82,976,284 | 2.00% | 0.01% |
| June 3, 2025 | Editas Medicine, Inc. | $EDIT | O'Neill Gilmore Neil | CEO | S | Common Stock | 15192 | $1.72 | 280,282.0000 | 82,976,284 | 5.14% | 0.02% |
| March 8, 2025 | Editas Medicine, Inc. | $EDIT | O'Neill Gilmore Neil | CEO | A | Stock Option (right to buy) | 828000 | $0.00 | 828,000.0000 | 82,976,284 | 9999.99% | 1.00% |
| March 8, 2025 | Editas Medicine, Inc. | $EDIT | O'Neill Gilmore Neil | CEO | A | Stock Option (right to buy) | 175000 | $0.00 | 175,000.0000 | 82,976,284 | 9999.99% | 0.21% |
| March 4, 2025 | Editas Medicine, Inc. | $EDIT | O'Neill Gilmore Neil | CEO | S | Common Stock | 16632 | $1.71 | 295,474.0000 | 82,976,284 | 5.33% | 0.02% |
| Dec. 3, 2024 | Editas Medicine, Inc. | $EDIT | O'Neill Gilmore Neil | CEO | S | Common Stock | 1618 | $2.08 | 312,106.0000 | 0 | 0.52% | 0.00% |
| Sept. 4, 2024 | Editas Medicine, Inc. | $EDIT | O'Neill Gilmore Neil | CEO | S | Common Stock | 1555 | $3.42 | 313,724.0000 | 0 | 0.49% | 0.00% |
| June 21, 2024 | Unity Biotechnology, Inc. | $UNBX | O'Neill Gilmore Neil | Not found | A | Stock Option (Right to Buy) | 10000 | $0.00 | 10,000.0000 | 0 | 9999.99% | 0.00% |
| June 4, 2024 | Editas Medicine, Inc. | $EDIT | O'Neill Gilmore Neil | CEO | S | Common Stock | 12191 | $5.50 | 315,279.0000 | 0 | 3.72% | 0.00% |
| March 2, 2024 | Editas Medicine, Inc. | $EDIT | O'Neill Gilmore Neil | CEO | A | Stock Option (right to buy) | 392100 | $0.00 | 392,100.0000 | 0 | 9999.99% | 0.00% |
| March 2, 2024 | Editas Medicine, Inc. | $EDIT | O'Neill Gilmore Neil | CEO | A | Common Stock | 72212 | $0.00 | 405,294.0000 | 0 | 21.68% | 0.00% |
| March 5, 2024 | Editas Medicine, Inc. | $EDIT | O'Neill Gilmore Neil | CEO | S | Common Stock | 77824 | $9.42 | 327,470.0000 | 0 | 19.20% | 0.00% |
| March 2, 2024 | Editas Medicine, Inc. | $EDIT | O'Neill Gilmore Neil | CEO | A | Common Stock | 72213 | $0.00 | 333,082.0000 | 0 | 27.68% | 0.00% |
| March 2, 2024 | Editas Medicine, Inc. | $EDIT | O'Neill Gilmore Neil | CEO | A | Common Stock | 130700 | $0.00 | 260,869.0000 | 0 | 100.41% | 0.00% |
| June 5, 2023 | Editas Medicine, Inc. | $EDIT | O'Neill Gilmore Neil | CEO | S | Common Stock | 6486 | $9.50 | 130,169.0000 | 0 | 4.75% | 0.00% |
| March 2, 2023 | Editas Medicine, Inc. | $EDIT | O'Neill Gilmore Neil | CEO | A | Stock Option (right to buy) | 150000 | $0.00 | 150,000.0000 | 0 | 9999.99% | 0.00% |
| March 2, 2023 | Editas Medicine, Inc. | $EDIT | O'Neill Gilmore Neil | CEO | A | Common Stock | 50000 | $0.00 | 136,655.0000 | 0 | 57.70% | 0.00% |